retatrutide glp-1 gip glucagon receptor agonist mechanism triple What GLP‑3 Really Is: Retatrutide Triple‑Receptor Drug Diagram showing the mechanism of

Moreover, an open-label trial tested exenatide, a GLP-1 RA, as a potential treatment for PD in a no-randomized, open-label study with 45 patients

Patients with proliferative retinopathy should be referred for treatment according to standards of care established by pivotal studies such as the Diabetic Retinopathy Study, the ETDRS, and the Diabetic Retinopathy Clinical Research Network (DRCR) Protocol S ( Figure 1 )

Triple agonists take this strategy further by targeting GLP-1R, GIPR, and the glucagon receptor (GCGR), aiming to regulate multiple complementary metabolic pathways

Orforgliprons approval highlights both the growing role of GLP-1 therapies in weight loss and the potential for faster regulatory pathways, bringing new treatments to patients sooner

Current Landscape As of 2024, exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide are the globally available GLP-1-RAs

Cytokines and chemokines in idiopathic intracranial hypertension